Cartesian Therapeutics Inc (RNAC)
19.12
-0.56
(-2.85%)
USD |
NASDAQ |
Nov 04, 16:00
19.12
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Net Income (Quarterly): 13.84M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 13.84M |
| March 31, 2024 | -56.82M |
| December 31, 2023 | -177.66M |
| September 30, 2023 | -9.002M |
| June 30, 2023 | -11.39M |
| March 31, 2023 | -21.66M |
| December 31, 2022 | 5.893M |
| September 30, 2022 | -7.893M |
| June 30, 2022 | 8.601M |
| March 31, 2022 | 28.78M |
| December 31, 2021 | 12.24M |
| September 30, 2021 | -17.89M |
| June 30, 2021 | 4.565M |
| March 31, 2021 | -24.60M |
| December 31, 2020 | -15.45M |
| September 30, 2020 | -9.729M |
| June 30, 2020 | -24.08M |
| March 31, 2020 | -19.62M |
| December 31, 2019 | -14.89M |
| Date | Value |
|---|---|
| September 30, 2019 | -11.99M |
| June 30, 2019 | -16.39M |
| March 31, 2019 | -12.07M |
| December 31, 2018 | -14.65M |
| September 30, 2018 | -16.00M |
| June 30, 2018 | -18.80M |
| March 31, 2018 | -15.89M |
| December 31, 2017 | -19.54M |
| September 30, 2017 | -14.68M |
| June 30, 2017 | -15.97M |
| March 31, 2017 | -15.13M |
| December 31, 2016 | -14.08M |
| September 30, 2016 | -7.728M |
| June 30, 2016 | -6.923M |
| March 31, 2016 | -7.476M |
| December 31, 2015 | -6.849M |
| September 30, 2015 | -5.725M |
| June 30, 2015 | -6.867M |
| March 31, 2015 | -5.733M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-177.66M
Minimum
Dec 2023
28.78M
Maximum
Mar 2022
-17.72M
Average
-11.39M
Median
Jun 2023
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -111.57M |
| Amgen Inc | 2.83B |
| Johnson & Johnson | 2.694B |
| Regeneron Pharmaceuticals Inc | 1.341B |
| NovaBay Pharmaceuticals Inc | -1.585M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 33.44M |
| Total Expenses (Quarterly) | 19.69M |
| EPS Diluted (Quarterly) | 0.54 |
| Enterprise Value | 369.67M |
| Profit Margin (Quarterly) | 41.37% |
| Earnings Yield | -279.6% |
| Normalized Earnings Yield | -99.19 |